# Jin et al. 2017 - Vi-TT Conjugate Vaccine Efficacy in Controlled Human Infection Model

## Citation

Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, Harris V, Gardner J, Nebykova A, Kerridge SA, Hill J, Thomaides-Brears H, Blohmke CJ, Yu L-M, Angus B, Pollard AJ. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of *Salmonella* Typhi: a randomised controlled, phase 2b trial. *Lancet*. 2017;390:2472-2480. doi:10.1016/S0140-6736(17)32149-9

**ClinicalTrials.gov:** NCT02324751

---

## Study Overview

| Parameter | Details |
|-----------|---------|
| **Study Type** | Randomised controlled, phase 2b, observer/participant-masked trial |
| **Study Design** | Controlled human infection model (CHIM) |
| **Location** | Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK |
| **Enrollment Period** | August 18, 2015 - November 4, 2016 |
| **Primary Objective** | Assess efficacy of Vi-tetanus toxoid conjugate vaccine (Vi-TT) against typhoid fever in controlled human challenge |
| **Funding** | Bill & Melinda Gates Foundation; European Commission FP7 (ADITEC) |

---

## Challenge Protocol

### Strain Information

| Parameter | Details |
|-----------|---------|
| **Organism** | *Salmonella enterica* serovar Typhi (*S.* Typhi) |
| **Strain** | Quailes strain |
| **Strain Origin** | Wild-type strain originally isolated from a chronic carrier in Baltimore, MD, USA |
| **Strain Characteristics** | Wild-type (not attenuated) |

### Challenge Dose and Delivery

| Parameter | Details | Page Ref |
|-----------|---------|----------|
| **Challenge Dose** | 1-5 × 10^4 CFU | p.2474 |
| **Route** | Oral ingestion | p.2474 |
| **Pre-treatment** | 120 mL sodium bicarbonate solution (to neutralize gastric acid) immediately before challenge | p.2474 |
| **Timing Post-vaccination** | ~1 month (median 28 days, range 25-40 days) | p.2474, 2476 |

### Rationale for Dose Selection

The authors note (p.2478):
- Historical studies by Woodward showed that larger inocula (10^6 or 10^7 CFU) overwhelmed vaccine protection
- The 10^4 CFU dose combined with sodium bicarbonate buffer "probably represents a high infecting inoculum" based on the 77% attack rate in controls
- The natural infecting dose of *S.* Typhi in endemic settings is unknown

---

## Subject Characteristics

### Inclusion Criteria (from text and appendix reference, p.2473)

- Healthy adult volunteers
- Age 18-60 years
- No previous history of typhoid vaccination
- No previous typhoid infection
- No prolonged residency in typhoid-endemic regions

### Exclusion Criteria (screening process)

- Extensive medical screening including blood work
- Baseline anti-Vi IgG assessment
- Gallbladder ultrasound
- (Full criteria in appendix pp.8-10 of original paper)

### Enrolled Population Demographics

| Characteristic | Control (n=34) | Vi-TT (n=41) | Vi-PS (n=37) |
|----------------|----------------|--------------|--------------|
| **Women** | 10 (29%) | 19 (46%) | 13 (35%) |
| **Men** | 24 (71%) | 22 (54%) | 24 (65%) |
| **Age, years (mean ± SD)** | 31.3 ± 11.9 | 31.2 ± 11.9 | 33.8 ± 12.0 |
| **Caucasian ethnicity** | 33 (97%) | 35 (85%) | 35 (95%) |
| **Other ethnicity** | 1 (3%) | 6 (15%) | 2 (5%) |

*Source: Table 1, p.2476*

---

## Baseline Immunity

| Parameter | Control | Vi-TT | Vi-PS | Notes |
|-----------|---------|-------|-------|-------|
| **Detectable baseline anti-Vi IgG (>7.4 EU/mL)** | 13 (38%) | 12 (29%) | 12 (32%) | Likely from exposure to cross-reactive bacteria (e.g., *Citrobacter* spp) |

*Source: Table 1, p.2476*

**Note:** Randomisation was stratified by baseline anti-Vi IgG titre to ensure participants with pre-existing detectable antibodies were equally distributed between groups (p.2474).

---

## Outcome Definitions

### Primary Endpoint: Typhoid Infection (Composite Definition)

Typhoid diagnosis met if **either**:
1. **Clinical criterion:** Persistent fever ≥38°C for ≥12 hours, OR
2. **Microbiological criterion:** *S.* Typhi bacteraemia (positive blood culture >72h post-challenge)

*Participants were denied access to antipyretics before diagnosis (p.2474)*

### Secondary Endpoints

| Endpoint Category | Specific Measures |
|-------------------|-------------------|
| **Safety** | Vaccine tolerability; severity scoring of solicited events (7 days post-vaccination, 21 days post-challenge) |
| **Time-to-event** | Time to typhoid diagnosis; time to first fever; time to bacteraemia |
| **Microbiological** | Quantitative blood culture (CFU/mL); stool culture positivity |
| **Immunogenicity** | Post-vaccination anti-Vi IgG titres; IgG subclass titres (IgG1, IgG2, IgG3); seroconversion (≥4-fold rise at day 28) |

### Alternative Diagnostic Criteria (Post-hoc Analyses)

- **Fever ≥38.0°C preceding *S.* Typhi bacteraemia**: Used to approximate field trial definitions
- Various fever thresholds: ≥37.5°C, ≥38.0°C, ≥38.5°C (any duration)

---

## Dose-Outcome Data Tables

### Primary Outcome: Attack Rates by Group (Per-Protocol Population)

| Group | n Challenged | n Completed | n Diagnosed | Attack Rate (%) | Relative Risk (95% CI) | Vaccine Efficacy (%, 95% CI) | p-value |
|-------|--------------|-------------|-------------|-----------------|------------------------|------------------------------|---------|
| **Control** | 32 | 31 | 24 | 77% | Reference | Reference | - |
| **Vi-TT** | 37 | 37 | 13 | 35% | 0.45 (0.28-0.73) | 54.6% (26.8-71.8) | 0.0005 |
| **Vi-PS** | 35 | 35 | 13 | 37% | 0.48 (0.30-0.77) | 52.0% (23.2-70.0) | 0.0010 |

*Source: Table 2, p.2476*

### Breakdown by Diagnosis Type

| Diagnosis Type | Control (n=31) | Vi-TT (n=37) | Vi-PS (n=35) |
|----------------|----------------|--------------|--------------|
| **Microbiological diagnosis** | 16/31 (52%) | 12/37 (32%) | 9/35 (26%) |
| **Clinical diagnosis only** | 8/31 (26%) | 1/37 (3%) | 4/35 (11%) |
| **S. Typhi bacteraemia among diagnosed** | 24/24 (100%) | 13/13 (100%) | 11/13 (85%) |

*Source: Table 2, p.2476*

### Fever Outcomes by Threshold

| Fever Threshold | Control (n=31) | Vi-TT (n=37) | Vi-PS (n=35) |
|-----------------|----------------|--------------|--------------|
| **≥37.5°C (any duration)** | 20/31 (65%) | 13/37 (35%) | 18/35 (51%) |
| **≥38.0°C (any duration)** | 17/31 (55%) | 6/37 (16%) | 11/35 (31%) |
| **≥38.5°C (any duration)** | 14/31 (45%) | 4/37 (11%) | 9/35 (25%) |

*Source: Table 2, p.2476*

### Alternative Endpoint: Fever ≥38°C Preceding Bacteraemia (Post-hoc)

| Group | Attack Rate | Vaccine Efficacy (%, 95% CI) |
|-------|-------------|------------------------------|
| **Control** | Reference | - |
| **Vi-TT** | - | 87.1% (47.2-96.9) |
| **Vi-PS** | - | 52.3% (-4.2-78.2) |

*Source: p.2477, Appendix p.1*

### Time-to-Event Outcomes (Median, IQR)

| Outcome | Control | Vi-TT | Vi-PS |
|---------|---------|-------|-------|
| **Time to diagnosis (days)** | 6.0 (5.1-7.8) | 6.5 (6.1-8.6) | 7.2 (5.9-10.2) |
| **Time to microbiological diagnosis (days)** | 6.0 (4.6-8.0) | 6.3 (6.0-8.3) | 6.1 (5.1-10.2) |
| **Time to clinical diagnosis (days)** | 6.8 (5.4-7.8) | 10.4 | 8.5 (6.5-10.0) |
| **Time to first fever ≥38°C (days)** | 7.2 (5.4-8.5) | 10.4 (10.2-15.5) | 7.5 (6.2-8.7) |
| **Time to first positive blood culture (days)** | 6.1 (5.0-7.6) | 6.5 (6.1-8.6) | 6.1 (5.0-10.2) |

*Source: Table 2, p.2476*

### Quantitative Blood Culture at Diagnosis

| Group | Median CFU/mL | Range |
|-------|---------------|-------|
| **Control** | 0.4 | 0.05-22.7 |
| **Vi-TT** | 0.075 | 0.05-1.2 |
| **Vi-PS** | 0.1 | 0.05-5.6 |

*Vi-TT vs Control: p=0.0476*
*Source: Table 2, p.2476-2477*

### Stool Culture Positivity

| Outcome | Control | Vi-TT | Vi-PS |
|---------|---------|-------|-------|
| **All participants with positive stool** | 22/31 (71%) | 22/37 (59%) | 21/35 (60%) |
| **Diagnosed participants with positive stool** | 19/24 (79%) | 12/13 (92%) | 10/13 (77%) |

*Source: Table 2, p.2476*

---

## Immunogenicity Data

### Seroconversion Rates (≥4-fold rise at Day 28)

| Group | Seroconversion Rate |
|-------|---------------------|
| **Vi-TT** | 100% |
| **Vi-PS** | 88.6% |

*Source: p.2477*

### Geometric Mean Titres (GMT) at Day 28 Post-Vaccination

| Group | GMT (EU/mL) | 95% CI |
|-------|-------------|--------|
| **Vi-TT** | 562.9 | 396.9-798.4 |
| **Vi-PS** | 140.5 | 91.0-216.9 |

*Vi-TT vs Vi-PS: p<0.0001 (adjusted for baseline)*
*Source: p.2477, Appendix p.2*

### Anti-Vi IgG by Diagnosis Status (at time of challenge)

| Group | Diagnosed GMT (EU/mL, 95% CI) | Undiagnosed GMT (EU/mL, 95% CI) | p-value |
|-------|-------------------------------|--------------------------------|---------|
| **Vi-TT** | - | - | p=0.84 (NS) |
| **Vi-PS** | 72.8 (43-122) | 207.5 (116-372) | p=0.0070 |

*Source: p.2477, Figure 3*

### Correlate of Protection Analysis

From adjusted logistic regression (p.2477):
- Higher anti-Vi IgG titres associated with lower odds of typhoid diagnosis
- **Odds Ratio:** 0.37 (95% CI: 0.15-0.88), p<0.0001
- Unadjusted for vaccine group: OR 0.35 (95% CI: 0.21-0.59), p=0.0001

**Important finding:** "An absolute threshold of protection, above which individuals are 100% protected from disease, could not be identified from these data" (p.2479)

---

## Data Quality Notes

### Strengths

| Aspect | Notes | Page Ref |
|--------|-------|----------|
| **Randomisation** | Computer-generated, block size 6, stratified by baseline Vi titre | p.2474 |
| **Masking** | Observer and participant-masked; unmasked nurses administered vaccines | p.2474 |
| **Challenge standardization** | Single strain, defined dose range, standardized sodium bicarbonate pre-treatment | p.2474 |
| **Daily monitoring** | Daily clinic visits with blood culture during 2-week challenge period | p.2474 |
| **Per-protocol analysis** | Pre-specified primary analysis | p.2474-2475 |

### Limitations

| Limitation | Impact | Page Ref |
|------------|--------|----------|
| **High challenge dose** | 10^4 CFU + bicarbonate may overwhelm vaccine protection; 77% control attack rate suggests high exposure | p.2478 |
| **Composite endpoint** | May include self-resolving asymptomatic bacteraemias that would go undetected in field studies | p.2478 |
| **Population** | Healthy typhoid-naive adults ≠ endemic population (children, pre-exposed individuals) | p.2478-2479 |
| **Early treatment** | Ethical requirement to treat early may affect attack rate estimates | p.2479 |
| **Randomisation ratio change** | Allocation ratio altered mid-study due to vaccine expiry (sensitivity analysis performed) | p.2474 |

### Data Completeness

| Item | Status |
|------|--------|
| **Enrolled** | 112 participants |
| **Per-protocol analyzed** | 103 participants (92% retention) |
| **Dropouts** | 8 pre-challenge (6 consent withdrawal, 1 IBD diagnosis, 1 elevated ALT); 1 protocol deviation |
| **Individual-level data** | Not provided; summary statistics only |

---

## Cross-References

### Related Oxford CHIM Studies

- **Waddington et al. 2014** (Ref 19): Establishment of the outpatient typhoid challenge model with escalating *S.* Typhi doses
- **Darton et al. 2016** (Ref 20): Ty21a and M01ZH09 vaccine efficacy using same challenge model

### Historical Challenge Studies

- **Woodward 1980** (Ref 22): Historical typhoid vaccine challenge studies from the 1960s showing dose-response relationships

### Comparator Efficacy Data

- **Lin et al. 2001** (Ref 15): Vi-rEPA conjugate vaccine, 89% efficacy in Vietnamese children aged 2-5 years (two doses)
- **Anwar et al. 2014** (Ref 11): Cochrane review; Vi-PS field efficacy ~69% in first year

### Subsequent Field Trials

- TyVAC (Typhoid Vaccine Acceleration Consortium) field trials mentioned as ongoing validation studies

---

## Fit Role Assessment

**Proposed Role: Core**

### Rationale

| Factor | Assessment |
|--------|------------|
| **Dose quantification** | Precise: 1-5 × 10^4 CFU (challenge inoculum well-characterized) |
| **Outcome definitions** | Clear primary endpoint; multiple secondary endpoints with alternative definitions |
| **Individual-level data** | Not available (summary statistics only), but group-level data suitable for dose-response modeling |
| **Baseline immunity characterization** | Anti-Vi IgG measured pre-vaccination; stratified randomization |
| **Relevance to dose-response modeling** | Single defined dose with attack rate data; provides anchor point for CHIM doses |

### [ASSISTANT-PROPOSED] Modeling Considerations

1. **Challenge dose interpretation**: The 1-5 × 10^4 CFU dose with sodium bicarbonate pre-treatment represents a "high" effective dose based on the 77% control attack rate. This should be considered an upper-bound challenge scenario.

2. **Endpoint selection for modeling**:
   - Primary composite endpoint (bacteraemia OR persistent fever ≥38°C for ≥12h): More inclusive, may underestimate field VE
   - Post-hoc "fever ≥38°C followed by bacteraemia": May better approximate clinical typhoid; VE = 87.1% for Vi-TT

3. **Control group as unvaccinated reference**: 77% attack rate at 10^4 CFU (with bicarbonate) provides a dose-response data point for naive individuals.

4. **Vaccine efficacy interpretation**: The study authors note that CHIM VE estimates are likely conservative due to the high challenge dose overwhelming vaccine-induced immunity.

---

## Open Questions

### [OPEN] Items Requiring Review

1. **Exact CFU administered per participant**: The dose is reported as "1-5 × 10^4 CFU" - was this a range across participants or uncertainty in inoculum preparation? Clarification needed for precise dose-response modeling.

2. **Bicarbonate effect quantification**: The sodium bicarbonate pre-treatment increases susceptibility by neutralizing gastric acid. Should an "effective dose multiplier" be applied to account for this?

3. **Integration with other CHIM studies**: How should attack rates from this study be combined with Waddington 2014 (dose-escalation without vaccine) and Darton 2016 (Ty21a/M01ZH09)?

4. **Baseline Vi titre effect**: 29-38% of participants had detectable baseline anti-Vi IgG. Was attack rate analyzed by baseline serostatus? (Not reported in main text)

5. **Individual-level data availability**: Would individual-level data (including exact challenge dose per participant, time-to-event, and anti-Vi titres) be available from authors or data repositories?

---

## Summary Statistics for Modeling

### Key Numbers (Control Group = Unvaccinated Reference)

| Parameter | Value | Notes |
|-----------|-------|-------|
| **Challenge dose** | 1-5 × 10^4 CFU | With 120mL sodium bicarbonate |
| **Strain** | Quailes (wild-type) | |
| **Control attack rate (composite)** | 24/31 = 77.4% | Bacteraemia OR fever ≥38°C ≥12h |
| **Control attack rate (fever + bacteraemia)** | ~42% | Estimated from VE calculation |
| **Control bacteraemia rate** | 24/31 = 77.4% | All diagnosed had bacteraemia |
| **Control fever ≥38°C rate** | 17/31 = 54.8% | Any duration |
| **Median time to diagnosis** | 6.0 days | IQR 5.1-7.8 |
| **Median blood CFU/mL** | 0.4 | Range 0.05-22.7 |

---

*Extract created: 2024*
*Source PDF pages: 1-9 (Lancet 2017; 390: 2472-2480)*
